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CORR E S POND ENC E
Impact of ﬂudarabine-based
induction therapy on outcome
of FLT32/NPM11
cytogenetically normal acute
myeloid leukemia
To the Editor:
We have read with great interest the manuscript by Sayar et al. entitled
“Long-term outcome of NPM1 mutated acute myeloid leukemia: A
single-institution experience.”1 The Authors report on 12 patients with
cytogenetically normal acute myeloid leukemia (CN-AML) with mutated
nucleophosmin (NPM11) and unmutated FLT3 (FLT32). Despite a high
complete remission (CR) rate with standard (713 cytarabine and idarubi-
cin) induction chemotherapy, all patients relapsed within 41 months, with
a median relapse-free survival (RFS) of 16.5 months. Eight out of
11 patients achieved a second CR, 6/8 underwent allogeneic stem cell
transplantation, and 3/6 patients are alive 6-18 months after transplant.
We reviewed our database and identiﬁed 51 patients treated for
FLT32/NPM11 CN-AML. There were 26 males and 25 females, with
a median age of 60 years (20-77). Induction chemotherapy consisted
of ﬂudarabine, cytarabine, and idarubicin in 34 patients and non-
ﬂudarabine-based (317 or hypomethylating agents—HMA) in 17
patients. All patients achieving CR received consolidation chemother-
apy with 1-2 courses of high-dose cytarabine and idarubicin. Patients
considered at high risk of relapse for disease characteristics at diagno-
sis (hyperleukocytosis, secondary AML) or poor response to induction
therapy were considered candidates for allogeneic stem cell transplan-
tation (SCT) from sibling or unrelated donors.
Overall, 41/51 patients (80%) achieved CR after induction therapy;
CR rate was signiﬁcantly higher in patients receiving ﬂudarabine-based
induction (31/34, 91%) compared to the non-ﬂudarabine group (10/17,
59%; v2512.4; P< .001). Of the 40 patients attaining CR who were
evaluable (1 was lost to follow-up), 27 maintained remission while 13
(32.5%) relapsed, with a 3-year RFS of 67%, without diﬀerence in
patients receiving or not ﬂudarabine in induction (69% vs. 58%). Twelve
patients underwent allogeneic SCT in ﬁrst line for high-risk features or
poor response to induction therapy, while ﬁve patients were trans-
planted after relapse and reinduction. Overall survival (OS) at 3 years
was 53%, with a signiﬁcant correlation according to induction therapy:
3-year OS for patients receiving ﬂudarabine was 64% compared to 32%
in patients treated with 317 or HMA (P5 .0012) (Figure 1).
Based on our previous observation of a negative impact of ABCG2
over-expression in AML,2 we analyzed the impact of ABCG2 expres-
sion in this cohort of FLT3-/NPM11 CN-AML patients. ABCG2 was
over-expressed in 29/51(57%) cases. As previously reported, ABCG2
status did not impact on CR rates (23/29, 79% in ABCG21 and 18/22,
82% in ABCG22 patients), independently of the induction type. There
was a trend for a lower 3-year RFS (61% vs. 74%) and 3-year OS (43%
and 68%) in ABCG2 overexpressing patients, that however did not
reach statistical signiﬁcance (P5 .2 for RFS and P5 .09 for OS), prob-
ably due to the limited number of cases. Combining induction therapy
and ABCG2 status, we found the best outcomes in ABCG22 patients
receiving ﬂudarabine (3-year DFS and OS 84%), while the few non-
ﬂudarabine treated ABCG22 patients had a dismal prognosis (3-year
DFS and OS 20% and 33%, respectively). As expected,3 in ABCG21
cases, ﬂudarabine was not able to completely overcome the negative
impact of ABCG2 expression, as long-term survival of ﬂudarabine-
treated patients was non-statistically superior compared to those
receiving 317 or HMA (3-year OS 50% vs. 33%, P5 .08).
Although it is generally recognized that FLT32/NPM11 CN-AML
patients have a favorable survival probability, comparable to that of core-
binding factor leukemia,4 some experiences have reported a rather unsat-
isfactory long-term outcome, with 2- or 3-years RFS around 30%.1,5 Our
experience conﬁrms the high CR rate, particularly using ﬂudarabine-
based induction chemotherapy, but also quite long relapse-free and over-
all survivals (67% and 53% at 3 years, respectively). We and others6 have
found that inclusion of ﬂudarabine in induction course was associated
with excellent CR rates, relatively high OS, and acceptable toxicity.
Over-expression of multidrug resistance proteins, such as ABCG2, could
contribute to a higher relapse risk and inferior survival, though reasons of
AML recurrence still need to be fully explained.
In conclusion, our data support the use of a more intensive
approach also in patients with FLT32negative, NPM1-mutated
FIGURE 1 Overall Survival according to induction therapy
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CN-AML. However, further eﬀorts are needed to identify risk factors
for AML recurrence in this “favorable-risk” patients and, ultimately, to
optimize their management.
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